Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference
Top Cited Papers
Open Access
- 1 May 2010
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 21 (suppl_5) , v232-v243
- https://doi.org/10.1093/annonc/mdq194
Abstract
Despite the relevant progress achieved in the last 20 years, vomiting and, especially, nausea, continue to be two of the most distressing side-effects of cancer chemotherapy. In the late 1990s several professional organizations published recommendations on the optimal antiemetic prophylaxis in patients submitted to chemotherapy and radiotherapy.Keywords
This publication has 29 references indexed in Scilit:
- Phase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic ChemotherapyJournal of Clinical Oncology, 2009
- Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell supportJournal of Oncology Pharmacy Practice, 2009
- Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trialThe Lancet Oncology, 2009
- Chemotherapy-induced nausea and vomiting: ESMO Clinical Recommendations for prophylaxisAnnals of Oncology, 2009
- Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamideSupportive Care in Cancer, 2008
- Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomitingExpert Opinion on Investigational Drugs, 2007
- Electroacupuncture for Refractory Acute Emesis Caused by ChemotherapyThe Journal of Alternative and Complementary Medicine, 2006
- Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus ConferenceAnnals of Oncology, 2005
- Improved prevention of moderately emetogenic chemotherapy‐induced nausea and vomiting with palonosetron, a pharmacologically novel 5‐HT3 receptor antagonistCancer, 2003
- Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy‐induced nausea and vomitingCancer, 2003